BioSpace News Archive

Drug Development

Unum Therapeutics Looks to File IPO, Reveals Patient Deaths in Early Clinical Trial

In its IPO announcement last week Unum revealed early data from its Phase I non-Hodgkin lymphoma therapy that included toxicity concerns at higher dosing levels.

March 5, 2018
·
2 min read
·
Alex Keown
Drug Development

Dermira’s Acne Medication Olumacostat Glaseretil Tanks in Two Phase III Trials

Dermira plans to shutter the program and move on to more promising compounds.

March 5, 2018
·
2 min read
·
Mark Terry
Drug Development

Vanda Pharmaceuticals’ Hetlioz Shows Promise for Treating Jet Lag

Vanda Pharmaceuticals announced positive results from its JET8 Phase III clinical trial of Hetlioz for jet lag disorder.

March 5, 2018
·
3 min read
·
Mark Terry
Drug Development

G1 Therapeutics Unveils Positive Mid-Stage Data for Myelopreservation in SCLC Patients

A mid-stage program aimed at treating myelosuppression in lung cancer patients undergoing chemotherapy is yielding positive results.

March 5, 2018
·
2 min read
·
Alex Keown
FDA

Prometic Snags Rare Pediatric Disease Designation from the FDA for its Inter-Alpha-Inhibitor-Proteins

Shares of Prometic Life Sciences Inc. jumped this morning after securing the U.S. Food and Drug Administration’s Rare Pediatric Disease Designation.

March 5, 2018
·
2 min read
·
Alex Keown
Drug Development

Gilead’s Preclinical Combo Trial Might Eradicate HIV

Gilead Sciences announced promising results from a preclinical trial conducted with Beth Israel Deaconess Medical Center as part of an HIV eradication strategy.

March 5, 2018
·
3 min read
·
Mark Terry
Business

Vividion Therapeutics Snags $101M from Celgene

Celgene handed over $101 million in upfront monies to San Diego-based Vividion Therapeutics, Inc. as part of an agreement to develop small molecule therapies.

March 5, 2018
·
2 min read
·
Alex Keown
Owlstone Medical Raises $15 Million USD (£11 million GBP) To Drive Commercialization of Its Breath Biopsy Platform

Owlstone Medical Ltd. announced that it has raised $15 million (£11 million) to drive the global commercialization of its Breath Biopsy® platform.

March 5, 2018
·
2 min read
RightBio Metrics Wins A First Place Patient Safety Innovation Award for the RightSpot®

RightBio Metrics was recently honored with a first place Patient Safety Innovation Award.

March 5, 2018
·
2 min read
Deals

Quotidian Technical Highlights on Selected Generic Drugs Stocks -- Mallinckrodt, Momenta Pharma, Mylan, and Neurocrine Biosciences

WallStEquities.com is offering reports on MNK, MNTA, MYL, and NBIX which can be accessed for free by signing up to www.wallstequities.com/registration.

March 5, 2018
·
4 min read